<SEC-DOCUMENT>0001193125-26-271117.txt : 20260615
<SEC-HEADER>0001193125-26-271117.hdr.sgml : 20260615
<ACCEPTANCE-DATETIME>20260615161551
ACCESSION NUMBER:		0001193125-26-271117
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260615
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260615
DATE AS OF CHANGE:		20260615

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptive Biotechnologies Corp
		CENTRAL INDEX KEY:			0001478320
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				270907024
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38957
		FILM NUMBER:		261091025

	BUSINESS ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109
		BUSINESS PHONE:		206-659-0067

	MAIL ADDRESS:	
		STREET 1:		1165 EASTLAKE AVE E
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptive TCR Corp
		DATE OF NAME CHANGE:	20091209
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d65233d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:adpt="http://www.adaptivebiotech.com/20260615" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2026-06-15_to_2026-06-15">Adaptive Biotechnologies Corp</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-290">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-06-15_to_2026-06-15">0001478320</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="adpt-20260615.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-06-15_to_2026-06-15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001478320</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-06-15</xbrli:startDate> <xbrli:endDate>2026-06-15</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-301">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-06-15_to_2026-06-15" format="ixt:datemonthdayyearen" id="ixv-302">June 15, 2026</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">ADAPTIVE BIOTECHNOLOGIES CORPORATION</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-06-15_to_2026-06-15" format="ixt-sec:stateprovnameen" id="ixv-303">Washington</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-304">001-38957</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-305">27-0907024</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-306">1665 Eastlake Avenue East</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-307">Suite 200</ix:nonNumeric>,</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-308">Seattle</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-06-15_to_2026-06-15" format="ixt-sec:stateprovnameen" id="ixv-309">Washington</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-310">98102</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-311">(206)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-312">659-0067</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-06-15_to_2026-06-15" format="ixt-sec:boolballotbox" id="ixv-313">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-06-15_to_2026-06-15" format="ixt-sec:boolballotbox" id="ixv-314">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-06-15_to_2026-06-15" format="ixt-sec:boolballotbox" id="ixv-315">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-06-15_to_2026-06-15" format="ixt-sec:boolballotbox" id="ixv-316">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-317">Common stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-318">ADPT</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-06-15_to_2026-06-15" format="ixt-sec:exchnameen" id="ixv-319">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-06-15_to_2026-06-15" format="ixt-sec:boolballotbox" id="ixv-320">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;15, 2026, Adaptive Biotechnologies Corporation (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) issued a press release announcing that it intends to offer, subject to market conditions and other factors, $250&#160;million in aggregate principal amount of convertible senior notes due 2031 (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Notes</span></span>&#8221;) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Offering</span></span>&#8221;). The Company expects to grant a <span style="white-space:nowrap">13-day</span> option to the initial purchasers of the Notes to purchase up to an additional&#160;$37.5&#160;million aggregate principal amount of the Notes. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also on June&#160;15, 2026, the Company issued a second press release announcing its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Business Separation</span></span>&#8221;). A copy of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the press release relating to the Business Separation and in connection with the Offering, the Company is issuing a statement providing additional information relating to the Business Separation, which is attached as Exhibit 99.3 and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this Current Report on Form <span style="white-space:nowrap">8-K</span> nor the press releases or additional information incorporated herein constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company&#8217;s common stock, if any, issuable upon conversion of the Notes. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:98%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"><span style="font-weight:bold">Exhibit</span><br/><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d65233dex991.htm">Press Release dated June&#160;15, 2026 (Notes Offering) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d65233dex992.htm">Press Release dated June&#160;15, 2026 (Business Separation) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d65233dex993.htm">Company Statement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Adaptive Biotechnologies Corporation</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;15, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kyle Piskel</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Kyle Piskel</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d65233dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial
flexibility</I></B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to
$25</I></B><B><I></I></B><B><I>&nbsp;million of common stock to reduce potential dilution</I></B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD
business </I></B> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEATTLE&#8212;(GLOBE NEWSWIRE)&#8212;June 15, 2026&#8212;Adaptive Biotechnologies Corporation (&#8220;Adaptive
Biotechnologies&#8221;) (Nasdaq: ADPT) today announced its intention to offer, subject to market and other conditions, $250&nbsp;million aggregate principal amount of convertible senior notes due 2031 (the &#8220;notes&#8221;) in a private offering
to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Adaptive Biotechnologies also expects to grant the initial purchasers of the
notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5&nbsp;million aggregate principal amount of notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will be senior, unsecured obligations of Adaptive Biotechnologies, will accrue interest payable semi-annually in arrears and will mature on
July&nbsp;1, 2031, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Adaptive Biotechnologies will settle conversions by paying or
delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Adaptive Biotechnologies&#8217;s election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Adaptive Biotechnologies&#8217;s option at any time, and from
time to time, on or after July&nbsp;1, 2029 and on or before the 40th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Adaptive Biotechnologies&#8217;s common stock exceeds 130% of the
conversion price for a specified period of time and certain other conditions are satisfied. In addition, the notes will be redeemable, in whole and not in part, at Adaptive Biotechnologies&#8217;s option at any time, if the aggregate principal
amount of the notes that remain outstanding is less than 15% of the aggregate principal amount of notes initially issued under the indenture and certain other conditions are satisfied. The redemption price will be equal to the principal amount of
the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If certain corporate events that constitute a
&#8220;fundamental change&#8221; occur, then, subject to a limited exception, noteholders may require Adaptive Biotechnologies to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be
repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interest rate, initial conversion rate and
other terms of the notes will be determined at the pricing of the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adaptive Biotechnologies intends to use a portion of the net proceeds from the offering to fund the cost of
entering into the capped call transactions described below. Adaptive Biotechnologies expects to use up to $25&nbsp;million of the net proceeds from the offering to repurchase shares of its common stock concurrently with the pricing of the offering
in privately negotiated transactions effected through one of the initial purchasers of the notes or its affiliate, as Adaptive Biotechnologies&#8217;s agent. Adaptive Biotechnologies intends to use the remainder of the net proceeds from the offering
for the repayment of the OrbiMed Purchase Agreement, general corporate purposes and opportunistic initiatives in the MRD business. If the initial purchasers exercise their option to purchase additional notes, then Adaptive Biotechnologies intends to
use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below. The concurrent repurchases of shares of Adaptive Biotechnologies&#8217;s common stock described above may result
in Adaptive Biotechnologies&#8217;s common stock trading at prices that are higher than would be the case in the absence of these repurchases, which may result in a higher initial conversion price for the notes Adaptive Biotechnologies is offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the pricing of the notes, Adaptive Biotechnologies has been advised that J. Wood Capital Advisors LLC (&#8220;JWCA&#8221;), Adaptive
Biotechnologies&#8217;s financial advisor with respect to the offering, intends to purchase up to $10&nbsp;million of shares of common stock concurrently with the offering in privately negotiated transactions with institutional investors through one
of the initial purchasers or its affiliate (the &#8220;JWCA Purchase&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the pricing of the notes, Adaptive Biotechnologies
expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates or one or more other financial institutions (the &#8220;option counterparties&#8221;). The capped call transactions
are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of Adaptive Biotechnologies&#8217;s common stock that will initially underlie the notes. If the initial
purchasers exercise their option to purchase additional notes, then Adaptive Biotechnologies expects to enter into additional capped call transactions with the option counterparties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The capped call transactions are expected generally to reduce the potential dilution to Adaptive Biotechnologies&#8217;s common stock upon any conversion of
the notes and/or offset any potential cash payments Adaptive Biotechnologies is required to make in excess of the principal amount of converted notes, as the case may be, upon conversion of the notes. If, however, the market price per share of
Adaptive Biotechnologies&#8217;s common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such
potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with
establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to Adaptive Biotechnologies&#8217;s common stock and/or
purchase shares of Adaptive Biotechnologies&#8217;s common stock concurrently with or shortly after the pricing of the notes. This activity, as well as the JWCA Purchase, could increase (or reduce the size of any decrease in) the market price of
Adaptive Biotechnologies&#8217;s common stock or the notes at that time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the option counterparties or their respective affiliates may modify their hedge positions by
entering into or unwinding various derivatives with respect to Adaptive Biotechnologies&#8217;s common stock and/or purchasing or selling Adaptive Biotechnologies&#8217;s common stock or other securities of Adaptive Biotechnologies in secondary
market transactions following the pricing of the notes and prior to the maturity of the notes (and (x)&nbsp;are likely to do so during any observation period related to a conversion of notes or following any repurchase of notes by Adaptive
Biotechnologies in connection with any fundamental change and (y)&nbsp;may do so following any repurchase of notes by Adaptive Biotechnologies other than in connection with any fundamental change). This activity, as well as the JWCA Purchase, could
also cause or avoid an increase or decrease in the market price of Adaptive Biotechnologies&#8217;s common stock or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs during any observation period
related to a conversion of notes, it could affect the number of shares and value of the consideration that noteholders will receive upon conversion of the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the
Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other
applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or
any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Adaptive Biotechnologies
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adaptive Biotechnologies (&#8220;we&#8221; or &#8220;our&#8221;) is a commercial-stage biotechnology company focused on harnessing the inherent
biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature&#8217;s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has
prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to
partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the
diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes
forward-looking statements, including statements regarding the anticipated terms of the notes being offered, the completion, timing and size of the proposed offering, the intended use of the proceeds and the anticipated terms of, and the effects of
entering into, the capped call transactions described above. Forward-looking statements represent Adaptive Biotechnologies&#8217;s current expectations regarding future events and are subject to known and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market
conditions, including market interest rates, the trading price and volatility of Adaptive Biotechnologies&#8217;s common stock and risks relating to Adaptive Biotechnologies&#8217;s business, including those described in periodic reports that
Adaptive Biotechnologies files from time to time with the SEC. Adaptive Biotechnologies may not consummate the proposed offering described in this press release and, if the proposed offering is consummated, cannot provide any assurances regarding
the final terms of the offering or the notes or its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Adaptive
Biotechnologies does not undertake to update the statements included in this press release for subsequent developments, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karina Calzadilla, Vice President,
Investor Relations and FP&amp;A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">201-396-1687</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investors@adaptivebiotech.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Erica Jones, Associate Corporate
Communications Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">206-279-2423</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@adaptivebiotech.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d65233dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MRD has scaled into a profitable, category-leading MRD diagnostics business, while </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEATTLE, June&nbsp;15, 2026 (GLOBE NEWSWIRE) &#8211; Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on
translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is
evaluating strategic and structural alternatives for Immune Medicine to support its growth strategy, capital needs, and value creation opportunities outside of Adaptive, and expects to identify its preferred path to separation by <FONT
STYLE="white-space:nowrap">year-end</FONT> 2026. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since establishing MRD and Immune Medicine as separate operating segments under Adaptive in 2024, both
businesses have continued to advance. MRD has achieved significant scale, expanded reimbursement, strengthened its clinical evidence base and reached profitability, establishing clonoSEQ<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> as a
leading platform in MRD testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the same time, Immune Medicine has continued to build a uniquely differentiated discovery platform anchored by the
world&#8217;s largest clinically linked immune receptor dataset and enhanced by advances in <FONT STYLE="white-space:nowrap">AI-driven</FONT> discovery. The platform is increasingly demonstrating its potential to generate novel biological insights,
identify therapeutic targets, and accelerate the development of precision medicines. As Immune Medicine enters its next phase of growth, the company believes the value of its differentiated assets may be best realized outside of a diagnostic
commercial model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;When we completed our strategic review in 2024, we decided to continue developing both MRD and Immune Medicine within Adaptive
while increasing their operational independence,&#8221; said Chad Robins, Chief Executive Officer and <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of Adaptive Biotechnologies. &#8220;The progress achieved by both businesses has reinforced that
decision. As we look ahead, Adaptive will focus on expanding its leadership in MRD diagnostics, while pursuing the optimal path for Immune Medicine outside of Adaptive. We believe this separation is the best way to unlock the full potential of both
businesses, increasing their impact on patients and creating long-term value for shareholders.&#8221; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the MRD business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adaptive&#8217;s MRD business has achieved significant scale, profitability and expanded clinical utility. Revenue has grown from $103&nbsp;million in 2023 to
$212&nbsp;million in 2025 and the business has reported $15&nbsp;million in 2025 adjusted EBITDA <FONT STYLE="white-space:nowrap">(non-GAAP).</FONT> With more than 300&nbsp;million covered lives, over 175 EMR integrated accounts and greater than 180
active biopharma trials, clonoSEQ is increasingly embedded in routine clinical practice and drug development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Immune Medicine business
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immune Medicine has progressed its data and drug discovery capabilities to uncover causal immune drivers to enable precision medicine in autoimmune
diseases. With over 6&nbsp;million functional <FONT STYLE="white-space:nowrap">T-cell</FONT> receptor (TCR)-antigen pairs and well-characterized data sets on more than 10,000 patients, Immune Medicine is discovering pathogenic TCRs and the
disease-causing antigens they bind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that this process will result in any transaction or other outcome, or as to the timing or
terms of any such transaction. Adaptive does not intend to disclose further developments unless and until it determines that further disclosure is appropriate or required. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking
statements, including statements regarding Adaptive&#8217;s business strategies, strategic focus, review of strategic alternatives for Immune Medicine, potential sale, separation, partnership, licensing transaction or other strategic or operational
outcome involving Immune Medicine, the timing and outcome of any strategic review process, the growth, profitability, reimbursement, clinical adoption and commercial opportunity of the MRD business, the market opportunity for clonoSEQ, expected
margin expansion, disciplined capital allocation, company-wide profitability and plans and objectives for future operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases,
forward-looking statements can be identified by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; &#8220;focus,&#8221; &#8220;opportunity,&#8221;
&#8220;evaluate,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These statements involve risks, uncertainties and other factors that may cause actual results, levels of
activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under &#8220;Risk Factors,&#8221;
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in the documents Adaptive files with the Securities and Exchange Commission from time to time. Adaptive cautions that
forward-looking statements are based on a combination of facts and factors currently known to the company and projections of the future, about which Adaptive cannot be certain. As a result, the forward-looking statements may not prove to be
accurate. The forward-looking statements in this press release represent Adaptive&#8217;s views as of the date hereof. Adaptive undertakes no obligation to update any forward-looking statements for any reason, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADAPTIVE INVESTORS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Karina Calzadilla, Vice President,
Investor Relations and FP&amp;A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">201-396-1687</FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>investors@adaptivebiotech.com</U> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ADAPTIVE MEDIA
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Erica Jones, Associate Corporate Communications Director </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">206-279-2423</FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>media@adaptivebiotech.com</U> </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d65233dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its previous announcements regarding the planned separation of its Immune Medicine businesses and the launch of a convertible notes
offering, Adaptive Biotechnologies Inc. (&#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221;) is providing this statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Separation of Immune Medicine Business </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since establishing MRD and Immune Medicine as separate operating segments in 2024, both businesses have continued to advance. MRD has achieved significant
scale, expanded reimbursement, strengthened its clinical evidence base and reached profitability, establishing clonoSEQ<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> as a leading platform in MRD clinical and biopharma testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the same time, Immune Medicine has continued to build a uniquely differentiated discovery platform anchored by the world&#8217;s largest clinically linked
immune receptor dataset and enhanced by advances in <FONT STYLE="white-space:nowrap">AI-driven</FONT> discovery. The platform is increasingly demonstrating its potential to generate novel biological insights, identify therapeutic targets, and
accelerate the development of precision medicines. Immune Medicine has progressed its data and drug discovery capabilities to uncover causal immune drivers to enable precision medicine in autoimmune diseases. With over 6&nbsp;million functional <FONT
STYLE="white-space:nowrap">TCR-antigen</FONT> pairs and well-characterized data sets on more than 10,000 patients, Immune Medicine is discovering pathogenic TCRs and the disease-causing&nbsp;antigens they bind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Immune Medicine enters its next phase of growth, we believe the long-term potential of its differentiated assets may be best realized outside of a
diagnostic commercial model. As a result, we have reached an inflection point where we believe separating the businesses would enable each to pursue its distinct strategic priorities, capital requirements, and growth opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following a separation, Adaptive would continue as the MRD business, building on its leadership position in MRD diagnostics and biopharma testing. We are
evaluating strategic and structural alternatives for Immune Medicine to pursue its growth strategy, capital needs, and value creation opportunities outside of Adaptive, and expect to identify our preferred path to separation by year end. We believe
this path offers the greatest opportunity to unlock the full potential of both businesses and create long-term value for shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leadership for
Immune Medicine, where Dr.&nbsp;Harlan Robins, our Chief Scientific Officer, has been primarily focused, will be determined as its strategic alternatives become clearer. Additionally, in line with his continued obligations to Adaptive and as
approved by our board of directors, Dr.&nbsp;Robins formed a new data-sharing, cloud-computing company, where he is the founder and a director but not a paid employee. As the strategy for Immune Medicine is finalized, the allocation of
Dr.&nbsp;Robins&#8217; time may change. Executive leadership for Adaptive and the MRD business remains intact, and Dr.&nbsp;Robins continues to support research and development efforts for the MRD business. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Repayment of OrbiMed Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2022, we entered into a revenue interest purchase agreement (the &#8220;OrbiMed Purchase Agreement&#8221;) with OrbiMed Royalty&nbsp;&amp; Credit
Opportunities IV, LP (&#8220;OrbiMed&#8221;), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the &#8220;Purchasers&#8221;). Pursuant to the OrbiMed Purchase Agreement, we received
$124.4&nbsp;million from the Purchasers (the &#8220;Purchaser Payment&#8221;), net of expenses. As consideration for such payments, the Purchasers have a right to receive certain revenue interest payments from us each quarter based on a current rate
of five percent of all GAAP revenue, subject to adjustment in September 2028 as provided in the OrbiMed Purchase Agreement. OrbiMed will be entitled to 100% of the revenue interest payments until it has received a total cumulative value of 165% of
the Purchaser Payment (the &#8220;Return Cap&#8221;), unless full repayment of the amount of the Return Cap has not been made by September&nbsp;12, 2032, in which case the Return Cap shall be increased to 175% of the Purchaser Payment. To secure our
obligations under the OrbiMed Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the OrbiMed Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OrbiMed has waived various covenants in the OrbiMed Purchase Agreement that otherwise would have restricted our ability to conduct this offering and agreed to
allow us to repay the Purchaser Payment at a Return Cap of 156%, which results in a payoff amount of $156.9&nbsp;million.&nbsp;We intend to repay this amount using the proceeds from this offering, and then to terminate the OrbiMed Purchase
Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not realize the anticipated benefits of separating our Immune Medicine business from our MRD business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As our Immune Medicine business enters its next phase of growth, we believe the long-term potential of its differentiated assets may be best realized outside
of a diagnostic commercial model of our MRD business. However, we may not achieve the anticipated operational, financial, strategic and other benefits of the separation. If strategic and structural alternatives for Immune Medicine do not emerge, we
may not succeed in separating it from our MRD business, and any alternatives that do become available to us may have commercially challenging terms. Even if we do separate our Immune Medicine business, it may be unable to access the required
capital, personnel, technology, or other resources necessary for the businesses to separately pursue its growth opportunities. Whether or not the separation is successful, pursuing the separation may distract our management, require time and
resources, or adversely impact our operations, employee retention and morale, customer and partner retention, and other important relationships.&nbsp;As a result, we may not realize the anticipated benefits of separating our Immune Medicine business
from our MRD business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This statement includes forward-looking statements, including statements regarding the separation of the Immune Medicine business, repayment of the OrbiMed
Purchase Agreement, completion of the offering, and the expected amount and intended use of the net proceeds described above. Forward-looking statements represent Adaptive Biotechnologies&#8217; current expectations regarding future events and are
subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, the satisfaction of the
closing conditions related to the offering and risks relating to Adaptive Biotechnologies&#8217; business, including those described in periodic reports that Adaptive Biotechnologies files from time to time with the Securities and
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exchange Commission. Adaptive Biotechnologies may not consummate the separation of the Immune Medicine business, repayment of the OrbiMed Purchase Agreement, and the offering described in this
statement. The forward-looking statements included in this press release speak only as of the date of this press release, and Adaptive Biotechnologies does not undertake to update the statements included in this press release for subsequent
developments, except as required by law. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>adpt-20260615.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 6/16/2026 12:12:25 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:adpt="http://www.adaptivebiotech.com/20260615"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.adaptivebiotech.com/20260615"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adpt-20260615_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="adpt-20260615_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>adpt-20260615_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 6/16/2026 12:12:25 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>adpt-20260615_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 6/16/2026 12:12:25 AM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="adpt-20260615.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 15, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adaptive Biotechnologies Corp<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001478320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 15,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0907024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1665 Eastlake Avenue East<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">659-0067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADPT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d65233d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adpt-20260615.xsd</File>
    <File>adpt-20260615_lab.xml</File>
    <File>adpt-20260615_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d65233d8k.htm">d65233d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d65233d8k.htm": {
   "nsprefix": "adpt",
   "nsuri": "http://www.adaptivebiotech.com/20260615",
   "dts": {
    "schema": {
     "local": [
      "adpt-20260615.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "adpt-20260615_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adpt-20260615_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d65233d8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-06-15_to_2026-06-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d65233d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-06-15_to_2026-06-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d65233d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adaptivebiotech.com//20260615/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-26-271117-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-271117-xbrl.zip
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MNW'U:Y.WIIM)MYWKEW;;5T_5\+'7_P%02P,$%     @ ^*'/7)I*ESM_!@
MN$8  !4   !A9'!T+3(P,C8P-C$U7VQA8BYX;6S-G&UOVS80Q]\7Z'>X>6\V
MH+)C!\T0(VF1.<D0+&F"QMV&#4,A2XQ-3"8-4H[M;S]2#XT<4S(5GJH ?9 E
MWO_N+_^.H24Y)Q_7\P@>B9"4L]-.OWO0 <("'E(V/>TLI>?+@-(.R-AGH1]Q
M1DX[&R(['S^\?7/R@^?!^>75)_!@%L<+.>SU5JM5-WR@3/)H&2M)V0WXO >>
MEX\?C;_ 'VFZ(7PF$?$E@<'1P1'\NJ11.!P<J!>'_5^ZA\4@07RM!J$?DR$<
M]?I'/3T0^H.A^C-X#V<W<.'+F @&8SHGQ5B^V @ZG<7P4_ S)%'GG#$2160#
MEY3Y+*!^!/=YP>_@B@5=.(LB^*S#I*I2$O%(PFZF&E'VWU#_,]&UP]LW .HD
M,IGL.^WH4Y&=B?5$1%TNIJK8@\->'M)YBECOA*P.DX#^\?%Q+SE:'"VI::P2
M[_?^NKF^#V9D[GOJY*LW*\C22#J4R?YK'B3GT*) *!VA7WGY,$_O\OH#[[#?
M7<NP\T$GS,Z./R'1M=J"Q,-0\(A4)-:'D^R=;'R\6:CQ9!T3%I),^9LV#[)1
M,T$>4E6-7B(I2="=\L=>2*@FY+W>\/2&KO!']>+KB"O:SR8R%GX0;^>+]"GB
M(M^9F#CM&()ZVP7I<6<BV-+R19#KJ,T]_K,1O8"K]VT1>XEB'OX@^-Q819:.
M&PY^C2:1L4Q-DMK2S4V8]^5^G]=4J&A,$,F70N%5YZU-_'Q(E.&?7/O?D]Y3
M[M=2JII")+FN6Z\;DA<LIO'F,YE2G8C%G_PYL273'-L2H)5&>/D8%US+]9"H
M31/ 4P;0*9S9;:[N(L)UBW<#^6RNYFOU-[Z,_*DMP<^"6D+77#HW''2!U2"$
M1.DW9=#2SG0V4&@12]MJ,>;5D4HC_.A*K236OY--O8EU)[C5F;7,"J\8Y#ZW
M&@5Q)]<L!20Y0"5!FEX;*=TPO]:HWPWI<QXL==^,5?6V)&_'M 2PL7"^>\P%
MUUT=)$IS8=#*SFCBEUDDTK)6' SOB* \O&#AN?I@7I?'9\$M@VFVPBL&8:!J
M$,1F-DT!*@?H)&CX-E"ZD6/K^C$6"U<LX&+!17*IY#Y6^49\J>;VS8B'-3^3
M[9%J=2%A9Y-;A[@O,BSD<9<<6PDAR0A92M YD58@W\&783WR<G,8371)(_)I
M.9\04:]CBG&MMH?! #<?=P?_N18NY5H=4GDDH+'K-=!K530&J&-_?16JGS'T
M@:87QU]";:E(JPCOL\8M!KO#72F,2[I*!=NY<+EOU(JA"5[@!Z,ESL)0&9#9
M?]>4D7Z]=C *M-H*59;XGH'N+5 JBHM_IO\NWP"="6X9UCJF,1L&]%_@I1GT
M!Z[H#UX=^@-;] =-H#_X?NB/5[PQ])%L6*-?Z041_9':O!5COF(O K\8_AJP
M-]@Q0?\T# WYYY(- :_3 !>@$^'"CFV@"G4[%XB8)Y^';\6=X(^4!34OZY1I
MO ;@RXR9J'\V%@U]HVY#_*<7-A0Z>3;<)FC$2E4GU/"#V YW7,9^]#==U+_&
M:59X#:U@-F5JA*V1:&U@4&VH"=),H%)A7K=LSD95 UA[<7P&4!L4Q*\#_'9,
M6T\ F@KGN\><GO_;T4$"-_DYKY5Q.,6O<^O9/\MBW4#4#^5&=S/.:EXOWXUK
M"<A2 ]Q\W 5,LQ82G(DX).I8UPV;J;<(:9VBW4#]4] X)FS$Y_,ERZY'2EM:
M2X);0K;:"J\8Y )OA2 2P5D&V$[A3'&#A1=1KEN]&\[W/*(!C2F;WJ@5MZ!^
M9,NR*;(ED"M,\+(1+@B7J2'Q^R0/N;XSO$V57"2W5MUNV-X)HON#*"R2!\CT
MMV/$[<.#_<*A2J$EC"U,\7TC7;#>IXJ$MTH#Q3R0)H(DDS/H39LH O]")ZCH
M7TFY),*] 0PZKZ,-R@V:FV%G/&)+E&@WU1AIND;[HR%'E5U2RY;C\H8$2[6>
MVO0'DS&-(^MK'+MQ;2UMR@QP\W&G98U1"VM1DXF#4H=$WGU-TTB]6RN:&D6[
M@3H6OOZF^?UF/N'62_!G02TA:BZ=&PZZP&D00B(S4X94VIG*!@HM(FE;+<Z\
M>;$.9LHMJ?-%7'-LR_.GT0@O'X,QC^[J8<^E>0:<+^(V5[=Q3K4L'N/^WL6<
MB*GJFM\$7\4SM1A9^*SF]Q]+)%J]PU=MB^\=ZGZ/KT(6B?7LQEB>"-),D*5"
MNL?7H W#33Y;+\4=UVI+_\J5;!=-?_&(VO,_4$L#!!0    ( /BASUR"4TB1
MRP0  $PL   5    861P="TR,#(V,#8Q-5]P<F4N>&ULU9I=C^(V%(;O5]K_
MX*8WK=00 CML!PV[HLQ,A3I? K:M>K,R\0&L.G9DFP'^?>V 6P)A2F:W53P:
M\>'X/7Y]'L>)3:X^KE.&GD$J*G@OB!O-  %/!*%\W@N6*L0JH31 2F-.,!,<
M>L$&5/#QP]LW5]^$(;J^'3Z@$"VTSE0WBE:K58/,*%>"+;4)J1J)2",4AJ[^
M8/()_;IMKHM&P  K0*U.LX-^6E)&NJVF^=*.WS?:^R()V$9#!&OHHDX4=R);
M$<6MKOEO7:#^/;K!2H/D:$)3V->*;"/I?*'1=\GW*%=="\Z!,=B@6\HQ3RAF
M:.P,_X"&/&F@/F-H9&7*N%0@GX$T=E$9Y7]V[<O4>D=OWR#S9]+(55[:"VPR
M=KE83R5K"#DW=IOMR(F"?<WZ2+1JYY+X\O(RRH\6ZRM:5MLT$$>_W]^-DP6D
M.#0(#++DH"GCANB_U?OF+J+M05=?T:[*(]V)),_]&=U")VO8;Z&K%MJB,&Z%
M[;BQ5B3X8)O<9E4*!B.8(?O^:30LM(D)SC1]ABD5&I)%/K#R4=#LQ!>1QFO!
M1;J)K#2Z%LDR!:[=>Y^3&ZZIW@SY3,@T[U" \MQV%Q)FO0"33(<NFK7U[<@$
M^EPED-YDYNQ0-,T8!"C:ZU8FS1#B.J]]9PH* EAKX 2("V,[\-]V_,.6\6X@
MBZ20"'<FYP 5)(VY>(X(4-OBA?U@L[3-D/GR>2#,Y-&?*BUQHHN98';D".D*
M&9X"ZP4EHNAK&MIV=P1S:L-S_8!3.-=7N;9H;Y]E7R:%R%@F+JKY> 2R>$[L
M:D09EB9>F"S,].?4,RG2TE3M6A,O^162@.P%K5;#3 D!RB05TE0S)0%:*F-)
M9-8\9O88S$!*('?;))PTFSLUTZN"O.979M8W0Y78X7K+\/Q<6 >B^E(Z,.KP
MM+W!LQUF ],#B=G0S%7K7V!3[9PZ$M<7UPG##ML[;["Y:\#$I/%<6D5-?2$5
M?3HV'>_8/('Q:B[1Y-K<V5:%=""N/ZT#PP[;>V^PN7NI1,A,R#RW8Y-B&(BE
MF2XV T$JWFO\2ZCZ(CW+O@/\HV> ;RF#AV4Z!5F-YKZN[NCVO3I.EYYQFN#U
MD)@TT!G=+E)? ^UDD+H3/&E\A[/=] QGGQ"39+5[,PMEB*NA+ U0=XREIAW"
MV'N$K2]%V/(18>L?A/XLPPN=&9B/CW(B5OQ5 /?EGN#;M^S@^;9(WW4EOQ5[
ME$]2/%.["?P:@D<Q/,%XY-NQ]&?E7NC/DU :LS]H5GUU41[!$XX'KAW%"V\H
MVOFD+P%7X5;4U)=4T:=CX\_^B_U5BSTM!*^XSCO6U9?1L5?'R9\-E]^,/PU\
M(-)TR7?+''4NK!/B^A([8=AA\V<;92P83:BF?'YO+L:26FOG,2M3UA=8F5M'
MRY_-E"<)=LB!N5O*]]3MS]'R<38[?UI\*4)]Z;WD>D?QG3][* >]&2JU!/GE
M+$OB>$.TQ+OCZL_&RAB2I;48MZ83JMG9MY+'NOIR._;J./FS>S*1V#XU-]ZD
M4W'VY>Y 5%]"!T8='G_V1]P0NUDG"\SG4.6YH')M?6&5^W7,?-L'N4E!SLW8
M^UF*E5Z8^3W#O.+C)R="U)?@B[8=R/]A*^0J.DK-G2FPC\%NC]@7^U"G*?D+
M4$L#!!0    ( /BASUPI+PA^LQ   +YN   -    9#8U,C,S9#AK+FAT;>T=
M:W/:QO:[?\4.;6_L&0.2 -M@FP[!)*6UL0?H;>=^Z2S2 GLC)'57LN'^^GO.
MZH%X8P-VDCHSB9#V?=Z/W<W5S^.131Z9D-QUKC_H.>T#88[I6MP97'^H=>K-
MYH>?JT=70Q^J055'5BS&KS-#W_<J^?RX)^R<9&9NX#[FH2!O:$8I$U4,9-:?
M>$PFM?M4]G*N&.3CDIGJCNLXP2BI_/3TE%/=8P/+%WELD8=*6:C%!#?C=F.;
M.U]FFCT55".]7"[G56E<=:%F,H"A:84\%O>H9'%U:GG^3'5J4<_GCZS'79^9
MPYSICG )9]J9GBQC+/FRR<  >O[/N]N..60CFN6.]*EC)D,%OE@YL7(>2N.*
M7+I%0S]?LXJH1M)@O*JN#G4=6#/[\V/[=EK=7UY_6C7O"^K(OBM&U >JP9Y*
M6<W(&F>I3K) %3,=Q52RJ9^+;$%/8 F#\W5+G8,BEEISU!E5/LN'A7%5*?Q%
MNH2/,R0I?4\LIW4L25==37_(.1GD($8M>/C<MUGU(OO;53[\>70U8CXEV#S+
M_@[XXW6F[CH^<_QL%R@^0\SP[3KCL[&?5]WEH54^[) 0<M5SK4GURN*/1/H3
MFUUG+"X]FTZ0I5BF2J[XN(*UF8A^<\MB3O@;JK1"?B+<NL[\HHK^ E;^J^'
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ME]G,&[I.;!B>HIUN!V@9D!H0AEK0FG@X2B"LMR/YZ@ ^0SL[V7YCSZT+^'K
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M<2O4F%\M6N??YYB7HUMB#IV6YOU>"-.\9N,5 \JRR ;$N0&\@IL"?*;0-98
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MU')Y_I AY9//A93 HM/#O_"0_U]X_@]02P,$%     @ ^*'/7-]8Y&KY#
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M*"+[R"116=B(4I,"[)G-"<C$.6"31'NBCEG,$(BSYS?2QIW:LY%&?2Y$/B6
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M;BS<]M!/MST-*5I_&KK!^E.*>?6LV8@/J:4BD?!P?7F<,#=.]#2Q;BX'/Z(
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MA&U7C?CVXNPW/.1_#/AO4$L#!!0    ( /BASUS7A%&IAPT   @H   0
M9#8U,C,S9&5X.3DS+FAT;>U:VW+;1A)]9Q7_84J)7=DJDKK$=FR)5I4LR1&K
M%$LK<>/-O@V!(3G18 ;& **X7[^G>P8@2%V2]=K>?=A4*A'!N?3E=/?I!H=G
MXU_.#X=GIT<GA]W.<#P:GY\>GOZ]_^;-X,?A=OB(Y]MQ@1B^NSCY3;S[^?CB
M_.+J[=;'L]'X=$M<CW\[/WV[9;15_;G2LWFY_\$5F31;AZ+;P?YC94M5' Y/
M1K_6BQ<Z+>?[KP<OM=T2TNB9Q0%J6F[Q-9?ULDP6,VW[I<OW=_+R0,3/$U>6
M+@N/ILZ6?:__J?9W5Y^G,M-FN3_6F?+B@UJ(*Y=)W'1T/OKYP]NM@H3<.AR^
M.SR]F^N)+@5I+(;;[PZ'VY>D\D,2[.Y] 1$.1U8DSEJ5E-I9L=#E7.C2B[Q0
MM]I57DAK7643E<%H7A1J)HM4VYDHYTKD!M^J5'B5RT+R 6[*VT=95EDE?E&I
M3N ',:D\_N>]H@-3WFPDCIW3!DD2W*JBU!.CA'6E\MV.FTY5@8MZXBB5>:EO
ME7BG\54RM\ZXF<9)(YL,Q _/OWN]M[=SL% ]_FOW0,0GE:\?T)7QH:N*^/0O
M0I.:[E9'??#1E[)D30>"#/^PYW=??PF[P]E7*L%5XD3=*N-R-C"A.SC]X;M?
M?:&KAZ/#ZS6G;3KL7708[# Z_ ,@?A&AKC5 )A0\,#':S\DEOUR=L.LV99.^
M1IP2+E>D!%9[-0L8U5;L[>R]Z G(,F\C;RX!(D -RRN@MG1"IK<2UP[XJCG.
ME<E<PQV -%* GNI$VK+;\8DTJB?470YQ\&6A=#:I"L]0Z0$UA;(S8)IB@="?
M(/=@JQ&(H5217A/I%>M2*%R!90#>5$-7;72Y[*WKG1AGW?7I7X?7?VO,O;+E
M3R^?'0B.%MS0YURU#R]L'3Y'<!X,M['ID$PDA5&2H8TP+:?(@&094K01CP2:
M:)?/)=*C0-B1(0/TOVK..2HY WB9*5'BR]X]%Y,OUCPUJ;1)H5-E]:=*F:5(
M-24(V%\#!BD^^L3!*LN5MO#LW!7X;K+DZQ:N,"D%_^Y/!Q[IIYA!X<88.!)_
MW:BTV]%!F +AF9>N$*DLX;Z2S:7LG!##AT;T,.*&[R\^C)MJ,M>EZOM<)FK?
MND4AX9VC43\MD,7L<)N6'JXD'HAQR*71271> IP MS-25&7. F(!Y9R;D09)
M;T.&F0%U' D6AQER)V5'\JZVGNJ*[PD"8:FG; 8(HRI@1Y1D /H6:G4[,DF4
M"0>1K=)53J+L@&J0:$^I(HL>\H,'?098SPJ*MA (9#DV6UI4LY:/$ID'Z%,:
MAQ*H!/0%GE>>) \GL[T*7J"LI-IP7PZRO:Q*5V_1'H8CZ3Y2)>-#7SVW$Y\?
M (J&=DYQ&64]W!.<UNT\X;;Q\54?.4#/5H[+I2Y"&5LH8_H)HD<F(!0 ?QHT
M!EB\("$!/YA36K&[T]O9V<%6:&S)Z)O&@]=K\W#(RG+N<"?\! E613/JUR=#
M85W0+,KG:<42"+#IMXCA^T6>:95GQUMU5PKD%60]P&=6N$4Y[\%>8J(,)=C
M )R=];$E:R$Z\H>-Z):>39I)J$=G(&X1((8M[JK2 ^!,)+J=5,N9=9X GK@L
M4T5"IV8N568@CB@K IZ5*5D8+@AU1H:7M)V:2(1RIP']!>)%M<6NF4XD0*WB
MLG"526N<TI$$VQQ%HE)1(\JN22DXE!5"%&C6KN 8Z%%$H!P82/.ITD5@6QR:
MT7@H=+DK2J0_6O\-_/O>&>,6I*AL\;L6&PL*UTF:*@Y9A.I+;95>R-IT!BQ*
M1J"*!(C,=0X#>\V6CD5IY3C_6%WZB%L*U>VH6VFJ6/0;8](>?*J2LBJHM!D
MRTJ2U$/1XAY8U[T3C1R/6Z[\895*HR/H5O 'X"60IK9#VBBL+11V@30 4G1=
MDX7!02F3 >!4G2C4Z>L6B49M62I9 $TI:QW1U^TP2>4-3(^#R6<D$87$2J)E
M2*K&)3>\9%H9LQYDF]R(1&75VF$9-";K>;A"S9TA[SW)C;\(]LY7,,'EW<Z&
M[WHQ+D^*04B 9[) )X+=R'UP%MGW&#QN*JX3S38'/BZF^*\J>ERF)DI9"C\(
M"@%P25*A9.%<U C*,*DB_;7EU,, :0&MC:R)0I8!* #L0A7(,&FJ0W$Q !&@
M35UHZ*K(=2M*X\#V9NQMKF]-5)$?)-H F5-K$G@&Z3-QZ+O(<2FR0P)6 CT;
M_8/B9*N,) 9H%UR(^N0V[J% *:NT#UGSBN.&_I)V65MRS@6(D8)F#[8/<C27
M 2DE-69XA.H'4&>Y<4NE.*4RE8N!\V"HX>BIMB%=]W@YS..2NO?H=C84B1R-
MJ2'G?)18.\-EIW<JJ=A,9@TAZ^;;3$/(J9DD^R"CHU"'L-RT7>T9]H:O.)*H
M5,"O2.5,85J42$UQ:QD2R^9U36[>/AG]BK8I3ANZ'<'_#G,8:VG4>MBH[%[4
MT*-<SE1_@K"\Z4\4+E/[TBSDTF\A_+9SNN3L2ER/_H$@_'&K/I>G(?O?O>%_
MML3'T<GX[.W6[L[.LV;@<'SZ87QZ]3\W#XF=Z14RX;*FGA?%1 -)XK*"(XA/
M'"'?<7W\9JWIR HTRZ7*)@@,M)9[3![8:,1S+362P JX/543?HQLG-<"RT;@
M'P@K<1#QN%[-?(+31KWNRBV1>98!M,]EEA^(8UROT9Y>K%6BT:\]<7[9S$7B
M_OI00K^0R(5&<_N\,O!1>JL]\HHX/S_N">Z_#'H2Q=5T1N)S3DB1%G5H1RC>
M^(LZ#&J5"RI211GZ#07SM!6_;!;5,@W("+X"C:7@HZ6/&X=-3YT9;D?;\OWN
MWHO!BPV"7[B,3UG=]+  XC+ ;&4;JQAS5+,M=Q%'G!FHLL?2S,6P0DJ($/6]
MS:N85 (/U'N1/E%8@>)3(@T] )1X4A"\\H$]?JI@0<A(DX.4^),42540)1:4
M:FE AJR*<W-PW!@K2*OBYZ.CR_J.'D2=_![IATQ_KWS).-0;@'XM9#T*8T#_
M@0\&S7=UO:0B6YK0J5.B(6'HC,=UK; #C5[)Y;CV)W0L';&NI,HJ$Q 6. C.
MVWWU\AE7BS5[USY<\_"5 @FTXECF*]>"#5$M8"94M!,,UZ,,9:_YM-K.TE'=
M8\*0H>90/6YL%W"WBWRPM_/C'M=[])!P7D+VVC@*M3@8*W;WT5H_O6RL=4^I
M@1@3+X3?%9$ ^+S%&D*=_A/10F%+% )8 ) U&$$]"YL5B#ELK ^0X3+BCXW'
MH!-M3JB5;684S1AV&5NS-:352 >I0L*5Z/?576(JZML]9Y9439E;_0FD??4^
MI[Z</+V0C,);F(A&W]2-6QE'BD\+2ET^\$/Y;H$6/39'L;]$MM1)J8(7XLB/
M[>1L6I')B!K6\^Z09>E<P@>((+5AE!4XE0"W#T-%2")G+;A1Q+Q\]:P7$1FZ
M7M:$.-P2U[50_SV6#MZLI=%(CSZ&X+5I^WZ(&_?R%"+D_L(EU"O5Z;>E4J^F
M99;S.S/K>M"T:=)N9\/Y7WL&K_V-A]U,;.H=.ZDU_?XL>A$?$6/:?_'LLTC0
MQT!]*?G$44?(5,B;B<YY*C)1%H%$HZ9I>S!!"CSV_B5XAU9L4M9O0Z6._-/B
M_5='2%Q3I7ABA$1GWS?>F5M GH*%JWT67R3<\UE\7T$=8H^[(DNG]S8&&9Q(
MUOS+358S(1B(T?0_F'VDCF5$E!4SZJ:A>2TWN V%,>6)%J10IQ\$3HAL-)+K
M=W(RQ"6Q.Y:W4AN>B]%4(O@@OHNIS6NXR3-&V1F'(3P*PYXB_PH]);NFKO7.
MYPD$]4C6Z.3*UI?2=-O[2$EXP ;N&$<\/6)0GEZ!XL]58>L)&"[X ;D35]*@
MWRHZARI:37E;(Y35#(?>3]P?+FU,\#[.%9^.@\CPZPZFGIE=X3T82R^<5J?:
MUC+2-&4ZCCI"=D&4@9.'VA]5#7TT3_D;35@[F=)XG83565X?T  4:^HV'R=Q
M<!$+A;\S5_#[L%#?X[" "+]E8\6EO1:2<3Y4)X)?<*;%Z6C=?:PQFV/9KY#W
MNIU'$]]7+S'O7;&01=H_=^Z&Y+RN7S)_=GGYMR08K[W8)O9IJC0D!A;+1+&:
M)11#O&C]Z<:[__5W_O3D\9"\Q[=CU>]V'J*L-)LRJGWR/2(1IZJ4U@,/H>>!
MI^!9%4H&K:.&KF$FT#HI](1V34#M!N+]HR8@D6GZ@Z,?^_E!/:6JN[(@4B3G
M*UM-JY+H.S5"91BS\@R[19=OK%N$P*IL^+M@4A*>1#(=WI117DW"W%V2E@C:
MBE\:!'*'PT+5 VCHA13GU<C'')8C#%$ZFQ>BCR, C6_FV-&T[3%QH BA\T:5
M3&5US!KAU6ZI_50F+2\BX1KGP_"Q7AS20>B$VHX.K\KYVJ)%S?[(%:TBT  X
MJ+!R/0H;,IQV "DYF<=X;-='?V8RU4;5M)8R*<E*_^?Q#$E]'9HF'<;H-/G[
M__SO\W)5MW-Z%X:]XAC<0'O/9.=1U]25@F8T59;53<67R$T/=M-U^FEPNH8K
M:GH0V:O?$(V?#+(Z%3=[Z:40CZL-C0>$S^%WX:RA)KN6+HU3N_OK@W2/FBIU
M*HPR>&Y0RIO QO*T,=J?%BS,P"8>]$+1SV-:DW$B#7?TLPG!8YU M2C?&+EX
M:C".0GAQ\AL>\B\ _P502P$"% ,4    " #XH<]<*!$)^VP#  "M#   $0
M            @ $     861P="TR,#(V,#8Q-2YX<V102P$"% ,4    " #X
MH<]<FDJ7.W\&  "X1@  %0              @ &; P  861P="TR,#(V,#8Q
M-5]L86(N>&UL4$L! A0#%     @ ^*'/7()32)'+!   3"P  !4
M     ( !30H  &%D<'0M,C R-C V,35?<')E+GAM;%!+ 0(4 Q0    ( /BA
MSUPI+PA^LQ   +YN   -              "  4L/  !D-C4R,S-D.&LN:'1M
M4$L! A0#%     @ ^*'/7,UKL:PS$@  C$<  !               ( !*2
M &0V-3(S,V1E>#DY,2YH=&U02P$"% ,4    " #XH<]<WUCD:OD,   3*
M$               @ &*,@  9#8U,C,S9&5X.3DR+FAT;5!+ 0(4 Q0    (
M /BASUS7A%&IAPT   @H   0              "  ;$_  !D-C4R,S-D97@Y
<.3,N:'1M4$L%!@     '  < N@$  &9-      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d65233d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adpt-20260615.xsd" xlink:type="simple"/>
    <context id="duration_2026-06-15_to_2026-06-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001478320</identifier>
        </entity>
        <period>
            <startDate>2026-06-15</startDate>
            <endDate>2026-06-15</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2026-06-15_to_2026-06-15"
      id="Hidden_dei_EntityRegistrantName">Adaptive Biotechnologies Corp</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-290">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-06-15_to_2026-06-15"
      id="Hidden_dei_EntityCentralIndexKey">0001478320</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-301">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-302">2026-06-15</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-303">WA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-304">001-38957</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-305">27-0907024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-306">1665 Eastlake Avenue East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-307">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-308">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-309">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-310">98102</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-311">(206)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-312">659-0067</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-313">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-314">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-315">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-316">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-317">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-318">ADPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-319">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-06-15_to_2026-06-15" id="ixv-320">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
